Enzymatic sialylation of IgA1 O-glycans: Implications for studies of IgA nephropathy

Kazuo Takahashi, Milan Raska, Milada Stuchlova Horynova, Stacy D. Hall, Knud Poulsen, Mogens Kilian, Yoshiyuki Hiki, Yukio Yuzawa, Zina Moldoveanu, Bruce A. Julian, Matthew B. Renfrow, Jan Novak

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Patients with IgA nephropathy (IgAN) have elevated circulating levels of IgA1 with some O-glycans consisting of galactose (Gal)-deficient N-acetylgalactosamine (GalNAc) with or without N-acetylneuraminic acid (NeuAc). We have analyzed O-glycosylation heterogeneity of naturally asialo-IgA1 (Ale) myeloma protein that mimics Gal-deficient IgA1 (Gd-IgA1) of patients with IgAN, except that IgA1 O-glycans of IgAN patients are frequently sialylated. Specifically, serum IgA1 of healthy controls has more α2,3-sialylated O-glycans (NeuAc attached to Gal) than α2,6-sialylated O-glycans (NeuAc attached to GalNAc). As IgA1-producing cells from IgAN patients have an increased activity of α2,6-sialyltransferase (ST6GalNAc), we hypothesize that such activity may promote premature sialylation of GalNAc and, thus, production of Gd-IgA1, as sialylation of GalNAc prevents subsequent Gal attachment. Distribution of NeuAc in IgA1 O-glycans may play an important role in the pathogenesis of IgAN. To better understand biological functions of NeuAc in IgA1, we established protocols for enzymatic sialylation leading to α2,3- or α2,6-sialylation of IgA1 O-glycans. Sialylation of Gal-deficient asialo-IgA1 (Ale) myeloma protein by an ST6GalNAc enzyme generated sialylated IgA1 that mimics the Gal-deficient IgA1 glycoforms in patients with IgAN, characterized by α2,6-sialylated Gal-deficient GalNAc. In contrast, sialylation of the same myeloma protein by an α2,3-sialyltransferase yielded IgA1 typical for healthy controls, characterized by α2,3- sialylated Gal. The GalNAc-specific lectin from Helix aspersa (HAA) is used to measure levels of Gd-IgA1. We assessed HAA binding to IgA1 sialylated at Gal or GalNAc. As expected, α2,6-sialylation of IgA1 markedly decreased reactivity with HAA. Notably, α2,3-sialylation also decreased reactivity with HAA. Neuraminidase treatment recovered the original HAA reactivity in both instances. These results suggest that binding of a GalNAc-specific lectin is modulated by sialylation of GalNAc as well as Gal in the clustered IgA1 O-glycans. Thus, enzymatic sialylation offers a useful model to test the role of NeuAc in reactivities of the clustered O-glycans with lectins.

Original languageEnglish
Article numbere99026
JournalPloS one
Volume9
Issue number6
DOIs
Publication statusPublished - 11-06-2014

Fingerprint

kidney diseases
galactose
Immunoglobulin A
Polysaccharides
polysaccharides
Helix aspersa
Acetylgalactosamine
Galactose
myeloma
acids
lectins
N-Acetylneuraminic Acid
Myeloma Proteins
sialidase
proteins
Sialyltransferases
glycosylation
Lectins
pathogenesis
Glycosylation

All Science Journal Classification (ASJC) codes

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)

Cite this

Takahashi, K., Raska, M., Horynova, M. S., Hall, S. D., Poulsen, K., Kilian, M., ... Novak, J. (2014). Enzymatic sialylation of IgA1 O-glycans: Implications for studies of IgA nephropathy. PloS one, 9(6), [e99026]. https://doi.org/10.1371/journal.pone.0099026
Takahashi, Kazuo ; Raska, Milan ; Horynova, Milada Stuchlova ; Hall, Stacy D. ; Poulsen, Knud ; Kilian, Mogens ; Hiki, Yoshiyuki ; Yuzawa, Yukio ; Moldoveanu, Zina ; Julian, Bruce A. ; Renfrow, Matthew B. ; Novak, Jan. / Enzymatic sialylation of IgA1 O-glycans : Implications for studies of IgA nephropathy. In: PloS one. 2014 ; Vol. 9, No. 6.
@article{c0d2fdcfb4a649cca9a795bd38f37c25,
title = "Enzymatic sialylation of IgA1 O-glycans: Implications for studies of IgA nephropathy",
abstract = "Patients with IgA nephropathy (IgAN) have elevated circulating levels of IgA1 with some O-glycans consisting of galactose (Gal)-deficient N-acetylgalactosamine (GalNAc) with or without N-acetylneuraminic acid (NeuAc). We have analyzed O-glycosylation heterogeneity of naturally asialo-IgA1 (Ale) myeloma protein that mimics Gal-deficient IgA1 (Gd-IgA1) of patients with IgAN, except that IgA1 O-glycans of IgAN patients are frequently sialylated. Specifically, serum IgA1 of healthy controls has more α2,3-sialylated O-glycans (NeuAc attached to Gal) than α2,6-sialylated O-glycans (NeuAc attached to GalNAc). As IgA1-producing cells from IgAN patients have an increased activity of α2,6-sialyltransferase (ST6GalNAc), we hypothesize that such activity may promote premature sialylation of GalNAc and, thus, production of Gd-IgA1, as sialylation of GalNAc prevents subsequent Gal attachment. Distribution of NeuAc in IgA1 O-glycans may play an important role in the pathogenesis of IgAN. To better understand biological functions of NeuAc in IgA1, we established protocols for enzymatic sialylation leading to α2,3- or α2,6-sialylation of IgA1 O-glycans. Sialylation of Gal-deficient asialo-IgA1 (Ale) myeloma protein by an ST6GalNAc enzyme generated sialylated IgA1 that mimics the Gal-deficient IgA1 glycoforms in patients with IgAN, characterized by α2,6-sialylated Gal-deficient GalNAc. In contrast, sialylation of the same myeloma protein by an α2,3-sialyltransferase yielded IgA1 typical for healthy controls, characterized by α2,3- sialylated Gal. The GalNAc-specific lectin from Helix aspersa (HAA) is used to measure levels of Gd-IgA1. We assessed HAA binding to IgA1 sialylated at Gal or GalNAc. As expected, α2,6-sialylation of IgA1 markedly decreased reactivity with HAA. Notably, α2,3-sialylation also decreased reactivity with HAA. Neuraminidase treatment recovered the original HAA reactivity in both instances. These results suggest that binding of a GalNAc-specific lectin is modulated by sialylation of GalNAc as well as Gal in the clustered IgA1 O-glycans. Thus, enzymatic sialylation offers a useful model to test the role of NeuAc in reactivities of the clustered O-glycans with lectins.",
author = "Kazuo Takahashi and Milan Raska and Horynova, {Milada Stuchlova} and Hall, {Stacy D.} and Knud Poulsen and Mogens Kilian and Yoshiyuki Hiki and Yukio Yuzawa and Zina Moldoveanu and Julian, {Bruce A.} and Renfrow, {Matthew B.} and Jan Novak",
year = "2014",
month = "6",
day = "11",
doi = "10.1371/journal.pone.0099026",
language = "English",
volume = "9",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "6",

}

Takahashi, K, Raska, M, Horynova, MS, Hall, SD, Poulsen, K, Kilian, M, Hiki, Y, Yuzawa, Y, Moldoveanu, Z, Julian, BA, Renfrow, MB & Novak, J 2014, 'Enzymatic sialylation of IgA1 O-glycans: Implications for studies of IgA nephropathy', PloS one, vol. 9, no. 6, e99026. https://doi.org/10.1371/journal.pone.0099026

Enzymatic sialylation of IgA1 O-glycans : Implications for studies of IgA nephropathy. / Takahashi, Kazuo; Raska, Milan; Horynova, Milada Stuchlova; Hall, Stacy D.; Poulsen, Knud; Kilian, Mogens; Hiki, Yoshiyuki; Yuzawa, Yukio; Moldoveanu, Zina; Julian, Bruce A.; Renfrow, Matthew B.; Novak, Jan.

In: PloS one, Vol. 9, No. 6, e99026, 11.06.2014.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Enzymatic sialylation of IgA1 O-glycans

T2 - Implications for studies of IgA nephropathy

AU - Takahashi, Kazuo

AU - Raska, Milan

AU - Horynova, Milada Stuchlova

AU - Hall, Stacy D.

AU - Poulsen, Knud

AU - Kilian, Mogens

AU - Hiki, Yoshiyuki

AU - Yuzawa, Yukio

AU - Moldoveanu, Zina

AU - Julian, Bruce A.

AU - Renfrow, Matthew B.

AU - Novak, Jan

PY - 2014/6/11

Y1 - 2014/6/11

N2 - Patients with IgA nephropathy (IgAN) have elevated circulating levels of IgA1 with some O-glycans consisting of galactose (Gal)-deficient N-acetylgalactosamine (GalNAc) with or without N-acetylneuraminic acid (NeuAc). We have analyzed O-glycosylation heterogeneity of naturally asialo-IgA1 (Ale) myeloma protein that mimics Gal-deficient IgA1 (Gd-IgA1) of patients with IgAN, except that IgA1 O-glycans of IgAN patients are frequently sialylated. Specifically, serum IgA1 of healthy controls has more α2,3-sialylated O-glycans (NeuAc attached to Gal) than α2,6-sialylated O-glycans (NeuAc attached to GalNAc). As IgA1-producing cells from IgAN patients have an increased activity of α2,6-sialyltransferase (ST6GalNAc), we hypothesize that such activity may promote premature sialylation of GalNAc and, thus, production of Gd-IgA1, as sialylation of GalNAc prevents subsequent Gal attachment. Distribution of NeuAc in IgA1 O-glycans may play an important role in the pathogenesis of IgAN. To better understand biological functions of NeuAc in IgA1, we established protocols for enzymatic sialylation leading to α2,3- or α2,6-sialylation of IgA1 O-glycans. Sialylation of Gal-deficient asialo-IgA1 (Ale) myeloma protein by an ST6GalNAc enzyme generated sialylated IgA1 that mimics the Gal-deficient IgA1 glycoforms in patients with IgAN, characterized by α2,6-sialylated Gal-deficient GalNAc. In contrast, sialylation of the same myeloma protein by an α2,3-sialyltransferase yielded IgA1 typical for healthy controls, characterized by α2,3- sialylated Gal. The GalNAc-specific lectin from Helix aspersa (HAA) is used to measure levels of Gd-IgA1. We assessed HAA binding to IgA1 sialylated at Gal or GalNAc. As expected, α2,6-sialylation of IgA1 markedly decreased reactivity with HAA. Notably, α2,3-sialylation also decreased reactivity with HAA. Neuraminidase treatment recovered the original HAA reactivity in both instances. These results suggest that binding of a GalNAc-specific lectin is modulated by sialylation of GalNAc as well as Gal in the clustered IgA1 O-glycans. Thus, enzymatic sialylation offers a useful model to test the role of NeuAc in reactivities of the clustered O-glycans with lectins.

AB - Patients with IgA nephropathy (IgAN) have elevated circulating levels of IgA1 with some O-glycans consisting of galactose (Gal)-deficient N-acetylgalactosamine (GalNAc) with or without N-acetylneuraminic acid (NeuAc). We have analyzed O-glycosylation heterogeneity of naturally asialo-IgA1 (Ale) myeloma protein that mimics Gal-deficient IgA1 (Gd-IgA1) of patients with IgAN, except that IgA1 O-glycans of IgAN patients are frequently sialylated. Specifically, serum IgA1 of healthy controls has more α2,3-sialylated O-glycans (NeuAc attached to Gal) than α2,6-sialylated O-glycans (NeuAc attached to GalNAc). As IgA1-producing cells from IgAN patients have an increased activity of α2,6-sialyltransferase (ST6GalNAc), we hypothesize that such activity may promote premature sialylation of GalNAc and, thus, production of Gd-IgA1, as sialylation of GalNAc prevents subsequent Gal attachment. Distribution of NeuAc in IgA1 O-glycans may play an important role in the pathogenesis of IgAN. To better understand biological functions of NeuAc in IgA1, we established protocols for enzymatic sialylation leading to α2,3- or α2,6-sialylation of IgA1 O-glycans. Sialylation of Gal-deficient asialo-IgA1 (Ale) myeloma protein by an ST6GalNAc enzyme generated sialylated IgA1 that mimics the Gal-deficient IgA1 glycoforms in patients with IgAN, characterized by α2,6-sialylated Gal-deficient GalNAc. In contrast, sialylation of the same myeloma protein by an α2,3-sialyltransferase yielded IgA1 typical for healthy controls, characterized by α2,3- sialylated Gal. The GalNAc-specific lectin from Helix aspersa (HAA) is used to measure levels of Gd-IgA1. We assessed HAA binding to IgA1 sialylated at Gal or GalNAc. As expected, α2,6-sialylation of IgA1 markedly decreased reactivity with HAA. Notably, α2,3-sialylation also decreased reactivity with HAA. Neuraminidase treatment recovered the original HAA reactivity in both instances. These results suggest that binding of a GalNAc-specific lectin is modulated by sialylation of GalNAc as well as Gal in the clustered IgA1 O-glycans. Thus, enzymatic sialylation offers a useful model to test the role of NeuAc in reactivities of the clustered O-glycans with lectins.

UR - http://www.scopus.com/inward/record.url?scp=84903372718&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84903372718&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0099026

DO - 10.1371/journal.pone.0099026

M3 - Article

C2 - 24918438

AN - SCOPUS:84903372718

VL - 9

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 6

M1 - e99026

ER -